July 18, 2024

Gregory J. Flesher
President and Chief Executive Officer
Reneo Pharmaceuticals, Inc.
18575 Jamboree Road, Suite 275-S
Irvine, CA 92612

        Re: Reneo Pharmaceuticals, Inc.
            Registration Statement on Form S-4
            Filed June 21, 2024
            File No. 333-280369
Dear Gregory J. Flesher:

       We have reviewed your registration statement and have the following
comments.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments.

Registration Statement on Form S-4
Following the Mergers, will Reneo's securities be traded on a stock exchange?,
page 12

1.     We note your disclosure that it is expected that the NewCo Class A
Common Stock will
       trade on the Nasdaq Global Market after completion of the Proposed
Transactions. Please
       revise to disclose if the terms of the merger agreement permit that the
Nasdaq listing
       closing condition could be waived without recirculation or
resolicitation. If so, please
       revise your risk factors to reflect the risks associated with any such
waiver and revise to
       indicate that shareholders may not have certainty at the time of the
vote that the shares of
       NewCo will be listed on Nasdaq following the merger or revise your
disclosure in a pre-
       effective amendment as appropriate if and when there is more certainty
regarding the
       Nasdaq listing of the NewCo Class A Common Stock.
 July 18, 2024
Page 2
Prospectus Summary
OnKure, Inc., page 20

2.     We note your disclosure here that OnKure is focused on developing
"best-in-
       class" precision medicines. Please revise this and similar statements
throughout the proxy
       statement/prospectus that OnKure's product candidates may be
"best-in-class" as these
       statements appear to be speculative given the current development status
of those product
       candidates and the noted length and uncertainty of the drug approval and
       commercialization processes.
3.     Please tell us your basis for your statement asserting that OnKure's
design platform is
       "proven" given that OnKure has no products approved for commercial sale.
Risk Factors, page 34

4.     We note from Section 10.1 of the Merger Agreement that, in general, the
representations
       and warranties of the parties contained in the Merger Agreement do not
survive the
       Closing and that there are no indemnification rights. Please include
appropriate risk factor
       disclosure.
OnKure contracts with third parties for the manufacture of its product
candidates for preclinical
studies..., page 80

5.     Please revise this risk factor to name the single-source supplier OnKure
currently relies
       upon and clarify if OnKure has entered into any supply agreements with
them.
The Amended Bylaws will provide that, unless NewCo consents in writing to the
selection of an
alternative forum..., page 91

6.     We note that your forum selection provision identifies the Court of
Chancery of the State
       of Delaware as the exclusive forum for certain litigation, including any
"derivative
       action." Please disclose whether this provision applies to actions
arising under
       the Exchange Act. In that regard, we note that Section 27 of the
Exchange Act creates
       exclusive federal jurisdiction over all suits brought to enforce any
duty or liability created
       by the Exchange Act or the rules and regulations thereunder. If this
provision does not
       apply to actions arising under the Exchange Act, please also ensure that
the exclusive
       forum provision in the governing documents states this clearly, or tell
us how you will
       inform investors in future filings that the provision does not apply to
any actions arising
       under the Exchange Act.
The Mergers
Background of the Mergers, page 104

7.     Please revise this section to provide a more fulsome description of the
negotiations related
       to the Concurrent PIPE Investments.
8.     Please revise to explain why the board of Reneo found the proposal from
OnKure "more
       attractive" than the proposal from Party B. Please also clearly disclose
when Reneo's
       board decided to stop considering the proposal from Party B.
9.     Please briefly explain why the Reneo board decided to also retain Cooley
LLP in
       connection with this transaction. In your revisions, provide a more
fulsome discussion of
       the role Cooley played in negotiating the merger agreement with OnKure.
 July 18, 2024
Page 3

10.    Please specify which terms remained under negotiation on April 26, 2024.
Opinion of Leerink Partners LLC
Certain Unaudited Financial Projections of OnKure, page 130

11.    Please revise to disclose the material assumptions underlying the
Reneo-prepared OnKure
       financial projections that were made available to Leerink Partners.
12.    We note the disclaimers throughout this section that readers are
cautioned not to rely on
       the prospective financial projections. While it is acceptable to include
qualifying language
       concerning subjective analyses, it is inappropriate to indicate that
investors cannot rely on
       disclosure. Please revise accordingly.
13.    We see in the OnKure Forecasts on page 132 the significant variances
among the amounts
       shown as projected net sales, adjusted net sales and adjusted net
revenue for the years
       presented. Briefly indicate how these terms were defined for purposes of
the forecasts and
       the reasons for the material differences.
OnKure Business, page 212

14.    Please revise your disclosure to remove any implication that OnKure's
product candidates
       will be safe or effective, as such conclusions are within the sole
authority of the FDA
       and comparable foreign regulators. By way of example only, on page 216
you state that
       OKI-219 causes "tumor regression" and has a "favorable safety profile."
We also note
       statements throughout OnKure's business section claiming your product
candidates are
       "more effective" than approved products or can "minimize known side
effects" observed
       in other PI3K   inhibitors. Please remove these statements, and any
others like them, or
       revise these statements to instead present the objective data resulting
from your
       clinical trials.
15.    Please indicate if the data presented in figure 1 (page 216), figure 7
(page 223) and
       figure 8 (page 224) was statistically significant, and include p-values
if appropriate.
OnKure's Clinical Pipeline, page 214

16.    Please revise your pipeline table to present all phases of clinical
development.
OnKure's Preclinical Pipeline, page 214

17.    We note the inclusion of OnKure's preclinical pipeline in this section.
Given the limited
       disclosure related to the programs contained in this pipeline table
throughout OnKure's
       Business section, please explain why they are sufficiently material to
OnKure's business
       to warrant inclusion here. If they are material, please expand the
disclosure in the
       Business section related to these candidates to provide a more fulsome
discussion of any
       development activities conducted. Alternatively, remove this pipeline
table.
OKI-219, a Targeted Inhibitor of PI3K  , page 216

18.    We note your disclosure in the last paragraph on page 215 that both
alpelisib and
       capivasertib are ATP-competitive kinase inhibitors. Please indicate if
OKI-219 is also an
       ATP-competitive kinase inhibitor or works by some other mechanism of
action.
 July 18, 2024
Page 4
19.    We note your disclosure that OnKure has shown preclinical data
supporting the selectivity
       of OKI-219 and that OKI-219 targets the H1047R mutated PI3K   with
approximately 80-
       fold selectivity over the wild-type PI3K  . Please disclose the material
data underlying
       this disclosure and indicate if such data was statistically significant,
providing p-values, if
       appropriate.
Commercial Opportunity in Breast Cancer, page 217

20.    Please revise this section to clearly state that you will need to
receive FDA approval prior
       to commercialization of any of your product candidates.
Limitations of Currently Approved PI3K Inhibitors, page 218

21.    Please identify the parties that conducted the clinical studies
referenced in this section that
       targeted mutated PI3K  . Please also clarify, if true, that OnKure did
not conduct any of
       the studies referenced here.
Phase 1 PIKture-01 Trial, page 224

22.    Please disclose the planned endpoints for all three parts of your Phase
1 PIKture-
       01 trial. Please also explain how this trial will be powered to assess
efficacy.
Figure 9. PIKture-01 trial design and timeline, page 225

23.    Please revise this graphic to ensure that all text is legible without
magnification.
Intellectual Property, page 228

24.    We note your statement here that OnKure's owned and licensed patent
portfolio consists
       of 128 patents and patent applications, including two licensed issued
patents. Please revise
       to clarify if any of the licensed patents are material to OnKure's
business. To the extent
       they are, please revise wherever appropriate to disclose the name of the
party or parties
       these patents are licensed from and discuss the material terms of the
licensing agreements
       related to these patents. Please also file these agreements as exhibits
to your registration
       statement. Refer to Item 601 of Regulation S-K for guidance.
PI3K Platform, page 228

25.    Please revise this section to the disclose the type of patent protection
and potential
       expiration dates, if granted, for each of the eleven patent families
relating to your PI3K
       platform. Please also discuss what a provisional patent application is
and what rights flow
       from this type of application.
Principal Stockholders of the Combined Company, page 326

26.    Please revise the footnotes to the table on page 327 to identify the
natural person(s) with
       voting and/or dispositive control over the shares in the combined
company that will
       be held by Acorn Bioventures, L.P., Cormorant Asset Management LP,
Perceptive Life
       Sciences Master Fund, Ltd. and Samsara BioCapital, L.P.
Exhibits

27.    We note you intend to file the form of preliminary proxy card as Exhibit
99.1. Please note
       that the form of proxy card should be filed as an appendix rather than
as an exhibit to the
 July 18, 2024
Page 5

       registration statement. Refer to the Note to paragraph (a)(3) of
Exchange Act Rule 14a-4.
General

28.    Please provide us your analysis as to whether Reneo Pharmaceuticals,
Inc. is a shell
       company as defined in Rule 12b-2 of the Exchange Act or whether it could
become one
       prior to the closing of the merger. For guidance, see Special Purpose
Acquisition
       Companies, Shell Companies, and Projections, Release No. 33-11265
(January 24, 2024)
       at nt. 943.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Gary Newberry at 202-551-3761 or Lynn Dicker at
202-551-3616 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Tim Buchmiller at 202-551-3635 with any
other
questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Jonn R. Beeson, Esq.